<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33175637</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6&#xae; cell-line: a phase 1 randomized controlled trial in adults.</ArticleTitle><Pagination><StartPage>1366</StartPage><EndPage>1373</EndPage><MedlinePgn>1366-1373</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2020.1812315</ELocationID><Abstract><AbstractText>This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6&#xae; cell line. Healthy adults (N&#xa0;=&#xa0;32) were randomized (1:1) to receive a single dose of PER.C6-based Sabin-IPV (sIPV, 15:35:112.5 DU/dose) or conventional Salk-IPV (cIPV, 40:8:32 DU/dose). Reactogenicity was assessed up to 7&#xa0;days after vaccination, immunogenicity 28&#xa0;days after vaccination, and safety up to 6&#xa0;months after vaccination.Solicited adverse events (AEs) were mild to moderate, no changes of concern in vital signs or safety laboratory values were observed, and no severe AEs (SAEs) or vaccine-related unsolicited AEs were reported after vaccination. A trend to more frequent solicited AEs after sIPV than after cIPV administration was observed. Most participants had preexisting neutralizing antibodies against poliovirus types (titer &#x2265;8), which were strongly boosted by sIPV. Post-vaccination geometric mean titers were high (&#x2265;12,000) and similar across the two vaccination groups. Only participants with very high preexisting antibody levels did not show a vaccine-induced response, defined in seropositive participants as a 4-fold titer increase. The 10 initially seronegative (titer &lt;8) participants (n&#xa0;=&#xa0;5 in each study group) seroconverted and all participants had seroprotective antibody levels post-vaccination. The antibodies elicited by sIPV neutralized both Sabin and Salk poliovirus strains.In conclusion, the PER.C6&#xae;-based sIPV was well tolerated and highly immunogenic in adults with preexisting antibodies to poliovirus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leroux-Roels</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroux-Roels</LastName><ForeName>Geert</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5968-2542</Identifier><AffiliationInfo><Affiliation>Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukarev</LastName><ForeName>Georgi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Vaccines AG, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuitemaker</LastName><ForeName>Hanneke</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8563-2266</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Conor</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7108-1168</Identifier><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rooij</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2255-2810</Identifier><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struijs</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Zeeburg</LastName><ForeName>Hester</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>DCPrime BV, Leiden the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquet</LastName><ForeName>Jeanne-Marie</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-7081-7022</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03032588</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Inactivated</Keyword><Keyword MajorTopicYN="N">PER.C6</Keyword><Keyword MajorTopicYN="N">Sabin</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33175637</ArticleId><ArticleId IdType="pmc">PMC8078678</ArticleId><ArticleId IdType="doi">10.1080/21645515.2020.1812315</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ward NA. Poliomyelitis: a review. Trop Doct. 1983;13:21&#x2013;28. doi:10.1177/004947558301300108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/004947558301300108</ArticleId><ArticleId IdType="pubmed">6836727</ArticleId></ArticleIdList></Reference><Reference><Citation>WHA 41st World Health Assembly . Global eradication of poliomyelitis by 2000. Geneva: 
World Health Organization; 
[resolution WHA41.28]. 1988. 
[accessed 2020 March16]. http://polioeradication.org/wp-content/uploads/2016/07/19880513_resolution-2.pdf.</Citation></Reference><Reference><Citation>Khan F, Datta SD, Quddus A, Vertefeuille JF, Burns CC, Jorba J, Wassilak SGF. Progress toward polio eradication &#x2014; worldwide, January 2016&#x2013;March 2018. MMWR Morb Mortal Wkly Rep. 2018;67(18):524&#x2013;28. doi:10.15585/mmwr.mm6718a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6718a4</ArticleId><ArticleId IdType="pmc">PMC5944975</ArticleId><ArticleId IdType="pubmed">29746452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaffran M, McGovern M, Hossaini R, Martin R, Wenger J. The polio endgame: securing a world free of all polioviruses. Lancet. 2018;391(10115):11&#x2013;13. doi:10.1016/S0140-6736(17)32442-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32442-X</ArticleId><ArticleId IdType="pubmed">29323639</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health organization . Global polio eradication initiative. Polio this week. 2020. 
[accessed 2020 March16]. http://polioeradication.org/polio-today/polio-now/this-week/.</Citation></Reference><Reference><Citation>Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(Suppl 1):S459&#x2013;464. doi:10.1093/infdis/jiu128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu128</ArticleId><ArticleId IdType="pubmed">25316868</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly . Poliomyelitis: mechanism for management of potential risks to eradication. Geneva: World Health Organization; 
[resolution WHA61.1]. 2008. 
[accessed 2020
March
16]. http://polioeradication.org/wp-content/uploads/2016/07/WHA61_Resolution_English.pdf.</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine &#x2014; worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(35):934&#x2013;38. doi:10.15585/mmwr.mm6535a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6535a3</ArticleId><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative . Polio eradication and endgame strategic plan 2013&#x2013;2018. 2013. 
[accessed 2020 March16]. http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.</Citation></Reference><Reference><Citation>World Health Organization . Meeting of the strategic advisory group of experts on immunization, November 2012 &#x2013; conclusions and recommendations. Polio eradication. Weekly Epidemiological Rec 2013;88:5&#x2013;7.</Citation></Reference><Reference><Citation>World Health Organization . Polio vaccines: WHO position paper - March 2016. Weekly Epidemiological Rec 2016;12:145&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative . Polio post-certification strategy: a risk mitigation strategy for a polio-free world. Geneva: World Health Organization. License: CC BY-NC-SA 3.0 IGO. 2018. 
[accessed 2020 March16]. http://polioeradication.org/wp-content/uploads/2018/04/polio-post-certification-strategy-20180424-2.pdf.</Citation></Reference><Reference><Citation>World Health Organization . Meeting of the strategic advisory group of experts on immunization, April 2017 &#x2013; conclusions and recommendations. Polio Eradication. Weekly Epidemiological Rec 2017;92:308&#x2013;10.</Citation></Reference><Reference><Citation>Okayasu H, Sein C, Hamidi A, Bakker WAM, Sutter RW. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals. 2016;44(6):581&#x2013;87. doi:10.1016/j.biologicals.2016.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2016.08.005</ArticleId><ArticleId IdType="pubmed">27720268</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlson S, Burlison J, Giles E, Fox H, Macadam AJ, Minor PD. New strains intended for the production of inactivated polio vaccine at low-containment after eradication. PLoS Pathog. 2015;11(12):e1005316. doi:10.1371/journal.ppat.1005316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005316</ArticleId><ArticleId IdType="pmc">PMC4699825</ArticleId><ArticleId IdType="pubmed">26720150</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D, Jarrahian C, Macklin G, Sutter RW. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization. J Infect Dis. 2017;216(Suppl 1):S161&#x2013;167. doi:10.1093/infdis/jix038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix038</ArticleId><ArticleId IdType="pmc">PMC5853966</ArticleId><ArticleId IdType="pubmed">28838185</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera L, Pedersen RS, Pe&#xf1;a L, Olsen KJ, Andreasen LV, Kromann I, Nielsen PI, S&#xf8;rensen C, Dietrich J, Bandyopadhyay AS, et al. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. Lancet Infect Dis. 2017;17(7):745&#x2013;53. doi:10.1016/S1473-3099(17)30177-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30177-9</ArticleId><ArticleId IdType="pmc">PMC5483484</ArticleId><ArticleId IdType="pubmed">28454674</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdijk P, Rots NY, MGCT VO, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WAM. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine. 2013;31(47):5531&#x2013;36. doi:10.1016/j.vaccine.2013.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.09.021</ArticleId><ArticleId IdType="pubmed">24063976</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Fonseca M, Alema&#xf1;i N, Diaza M, Martinez Y, Garcia G, Okayasu H, Burton A, Bakker WAM, et al. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I trial in healthy adults in Cuba. Vaccine. 2014;32(42):5399&#x2013;404. doi:10.1016/j.vaccine.2014.07.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.07.109</ArticleId><ArticleId IdType="pubmed">25131734</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237&#x2013;43. doi:10.1093/infdis/jir723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir723</ArticleId><ArticleId IdType="pubmed">22158682</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase. II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV). J Infect Dis. 2013;208(2):275&#x2013;83. doi:10.1093/infdis/jit155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit155</ArticleId><ArticleId IdType="pubmed">23568174</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdijk P, Rots NY, van Oijen MGCT, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WAM. Safety and immunogenicity of a primary series of Sabin-IPV with or without aluminium hydroxide in infants. Vaccine. 2014;32(39):4938&#x2013;44. doi:10.1016/j.vaccine.2014.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.07.029</ArticleId><ArticleId IdType="pubmed">25043278</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, et al. Phase 3 trial of a Sabin strain&#x2013;based inactivated poliovirus vaccine. J Infect Dis. 2016;214(11):1728&#x2013;34. doi:10.1093/infdis/jiw433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw433</ArticleId><ArticleId IdType="pubmed">27658691</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano T, Sumino S, Takanami Y, Mitsuya N, Nakatome K. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children. Hum Vaccin Immunother. 2018;14(12):2940&#x2013;49. doi:10.1080/21645515.2018.1504538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1504538</ArticleId><ArticleId IdType="pmc">PMC6343622</ArticleId><ArticleId IdType="pubmed">30047808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial. Vaccine. 2018;36(45):6782&#x2013;89. doi:10.1016/j.vaccine.2018.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.023</ArticleId><ArticleId IdType="pubmed">30249424</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34(16):1975&#x2013;85. doi:10.1016/j.vaccine.2014.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.11.015</ArticleId><ArticleId IdType="pubmed">25448090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders BP, Edo-Matas D, Custers JHHV, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WAM, Uytdehaag F, Goudsmit J, et al. PER.C6(&#xae;) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. Vaccine. 2013;31(5):850&#x2013;56. doi:10.1016/j.vaccine.2012.10.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.070</ArticleId><ArticleId IdType="pubmed">23123018</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders BP, de Los Rios Oakes I, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JHHV, Macadam A, et al. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(&#xae;) cell culture platform for the generation of safe and affordable next generation IPV. Vaccine. 2015;33(48):6611&#x2013;16. doi:10.1016/j.vaccine.2015.10.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.091</ArticleId><ArticleId IdType="pubmed">26529068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6&#xae; cell culture platform is immunogenic and safe in a non-human primate model. Vaccine. 2018;36(46):6979&#x2013;87. doi:10.1016/j.vaccine.2018.09.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.068</ArticleId><ArticleId IdType="pmc">PMC6219454</ArticleId><ArticleId IdType="pubmed">30314910</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013. Accessed on 16July 2020);310(20):2191&#x2013;94. doi:10.1001/jama.2013.281053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA . ICH good clinical practice guidelines. 2016. 
[accessed 2020 July16]. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf.</Citation></Reference><Reference><Citation>Food and Drug Administration . Center for biologics evaluation and research. guidance for industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. September.</Citation></Reference><Reference><Citation>World Health Organization . Expert committee on biological standardization (ECBS), sixty-fifth report. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). WHO Technical Report Series No. 993, Annex 3, 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">26714369</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145&#x2013;76. doi:10.1007/978-1-4939-3292-4_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3292-4_8</ArticleId><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>KCE Report 313 . Performance of the Belgian health system &#x2013; report
2019. [accessed 2020 July16]
https://www.healthybelgium.be/metadata/hspa/p1_p2_p3.pdf.</Citation></Reference><Reference><Citation>Murph JR, Grose C, McAndrew P, Mickiewicz C, Mento S, Cano F, Radick L, Ritchey M, Stout MG. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatric Infect Dis J. 1988;7(11):760&#x2013;65. doi:10.1097/00006454-198811000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-198811000-00003</ArticleId><ArticleId IdType="pubmed">2852791</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Expert committee on biological standardization Geneva, 29 October to 2 November 2018. Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV). 2018. 
[accessed 2020 March16]. http://www.who.int/biologicals/BS.2018.2338_sIPV_IS_Collaborative_Study_Report_version.pdf.</Citation></Reference><Reference><Citation>Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, et al. Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses. Clin Infect Dis. 2017;64(10):1317&#x2013;25. doi:10.1093/cid/cix110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix110</ArticleId><ArticleId IdType="pubmed">28419204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>